LNP-delivered mRNA Therapeutics with Applied BioMath Assess

Applied BioMath Assess enables early human dose predictions of LNP-delivered mRNA therapeutics. This case study estimates the dose of an mRNA replacement for UGT1A1 in Crigler-Najjar patients. It identifies dosing requirements and explores key design variables of the drug that impact feasibility of preferred dosing regimes.

Supplementary information, referenced in the case study, can be downloaded here.